• 1
    Bonina F., Santagati N.A., Puglia C. (2003) Ketoprofen 1-alkylazacycloalkan-2-one esters as dermal prodrugs: in vivo and in vitro evaluations. Drug Dev Ind Pharm;29:181190.
  • 2
    Bonina F., Puglia C., Santagati N.A., Saija A., Tomaino A., Tita B. (2002) Oligoethylene ester derivatives of ketoprofen, naproxen and diclofenac as oral prodrugs: a pharmacological evaluation. Pharmazie;57:552555.
  • 3
    Bonina F.P., Puglia C., Ventura D., Santagati N.A., Saija A., Trombetta D. (2002) 1-Ethyl and 1-propylazacycloalkan-2-one ester prodrugs of ketoprofen. Synthesis, chemical stability, enzymatic hydrolysis, anti-inflammatory activity, and gastrointestinal toxicity. Arzneim Forsch;52:884889.
  • 4
    Kalgutkar A.S., Crews B.C., Rowlinson S.W., Marnett A.B., Kozak K.R., Remmel R.P., Marnett L.J. (2000) Biochemicaly based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflamatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci USA;97:925930.
  • 5
    Flynn D.L., Capiris T., Cetenko W.J., Connor D.T., Dyer R.D., Kostlan C.R., Nies D.E., Schrier D.J., Sircar J.C. (1990) Nonsteroidal anti-inflammatory drug hydroxamic acids. Dual inhibitors of both cyclooxygenase and 5-lipoxygenase. J Med Chem;33:20702072.
  • 6
    Muri E.M.F., Nieto M.J., Sindelar R.D., Williamson J.S. (2002) Hydroxamic acids as pharmacological agents. Curr Med Chem;9:16311653.
  • 7
    Thun M.J., Henley S.J., Patrono C. (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst;94:252266.
  • 8
    Richter M., Weiss M., Weinberger I., Fürstenberger G., Marian B. (2001) Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors. Carcinogenesis;22:1725.
  • 9
    Gwyn K., Sinicrope F.A. (2002) Chemoprevention of colorectal cancer. Am J Gastroenterol;97:1321.
    Direct Link:
  • 10
    Husain S.S., Szabo I.L., Tarnawski A.S. (2002) NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action. Am J Gastroenterol;97:542553.
    Direct Link:
  • 11
    Sivak-Sears N.R., Schwartzbaum J.A., Miike R., Moghadassi M., Wrensch M. (2004) Case-control study of use of nonsteroidal antiinflammatory drugs and glioblastoma multiforme. Am J Epidemiol;159:11311139.
  • 12
    Sato M., Narisawa T., Sano M., Takahashi T., Goto A. (1983) Growth inhibition of translatable murinecolon adrenocarcinoma 38 by indomethacin. J Cancer Res Clin Oncol;106:2125.
  • 13
    Kobayashi S., Okada S., Yoshida H., Fujimura S. (1997) Indomethacin enhances the cytotoxicity of VCR and ADR in human pulmonary adenocarcinoma cells. J Exp Med;181:361370.
  • 14
    Marjanović M., Zorc B., Pejnović L., Zovko M., Kralj M. (2007) Fenoprofen and ketoprofen amides as potential antitumor agents. Chem Biol Drug Des;69:222226.
  • 15
    Wittine K., Benci K., Rajić Z., Zorc B., Kralj M., Marjanović M., Pavelić K., De Clercq E., Andrei G., Snoeck R., Balzarini J., Mintas M. (2008) The novel phosphoramidate prodrugs of NSAID 3-hydroxypropylamides: synthesis, cytostatic and antiviral activity evaluations. Eur J Med Chem;44:143151.
  • 16
    Rajić Z., Perković I., Butula I., Zorc B., Hadjipavlou-Litina D., Pontiki E., Pepeljnjak S., Kosalec I. (2009) Synthesis and biological evaluation of O-methyl and O-ethyl NSAID hydroxamic acids. J Enzyme Inhib Med Chem;24:11791187.
  • 17
    Zorc B., Antolić S., Butula I. (1993) Macromolecular prodrugs. I. Synthesis of some non-steroidal anti-inflammatory drug esters. Acta Pharm;43:127133.
  • 18
    Butula I., Jadrijević Mladar Takač M. (2000) Reaction with 1-benzotriazolecarboxylic acid chloride. VIII. Synthesis of N-hydroxyisocyanate derivatives. Croat Chem Acta;73:569574.
  • 19
    Zovko M., Zorc B., Jadrijević-Mladar Takač M., Metelko B., Novak P. (2003) The novel ketoprofenamides – synthesis and spectroscopic characterization. Croat Chem Acta;76:335341.
  • 20
    Comisso G., Sega A., Šunjić V. (1981) Synthesis, conformational studies and enantioselective homogeneous catalytic hydrogenation with CRC-PHOS, and some congeners. Croat Chem Acta;54:375395.
  • 21
    Allegretti M., Bertini R., Cesta M.C., Bizzarri C., Bitondo R., Di Cioccio V., Galliera E. et al. (2005) 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem;48:43124331.
  • 22
    Van Overbeke A., Baeyens W., Dewaele C. (1995) Comparative study on the enantiomeric separation of several non-steroidal anti-inflammatory drugs on two cellulose-bases chiral stationary phases. J Liq Chromatogr;18:24272443.
  • 23
    Pontiki E., Hadjipavlou-Litina D. (2007) Synthesis and pharmacochemical evaluation of novel aryl-acetic acid inhibitors of lipoxygenase, antioxidants, and anti-inflammatory agents. Bioorg Med Chem;15:58195827.
  • 24
    Re R., Pellegrini N., Proteggente A., Pannala A., Yang M., Rice-Evans C. (1999) Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Radic Biol Med;26:12311237.
  • 25
    Hattori K., Sajiki H., Hirota K. (2001) Chemoselective control of hydrofenation among aromatic carbonyl and benzyl alcohol derivatives using Pd/C(en) catalyst. Tetrahedron;57:48174824.
  • 26
    Taraborewala R.B., Kauffman J.M. (1990) Synthesis and structure-activity relationships of anti-inflammatory 9,10-dihydro-9-oxo-2-acridine-alkanoic acids and 4-(2-carboxyphenyl)aminobenzenealkanoic acids. J Pharm Sci;79:173178.
  • 27
    Kühn H., Belkner J., Wiesner R., Brash A.R. (1990) Oxygenation of biological membranes by the pure reticulocyte lipoxygenase. J Biol Chem;265:1835118361.
  • 28
    Pontiki E., Hadjipavlou-Litina D. (2005) Lipoxygenases superfamily (LOX): an interesting target for the development of inhibitors-promising drugs against cell differentiation, inflammation and carcinogenesis. Curr Enz Inh;1:309328.
  • 29
    Muller K. (1994) 5-Lipoxygenase and 12-lipoxygenase: attractive targets for the development of novel antipsoriatic drugs. Arch Pharm;327:319.
  • 30
    Pontiki E., Hadjipavlou-Litina D. (2002) Quantitative-structure activity relationships on lipoxygenase inhibitors. Internet Electron J Mol Des;1:134141.
  • 31
    Pontiki E., Hadjipavlou-Litina D. (2003) Review in quantitative structure activity relationships on lipoxygenase inhibitors. Mini Rev Med Chem;3:487499.
  • 32
    Franken N.A.P., Rodermond H.M., Stap J., Haveman J., Van Bree C. (2006) Clonogenic assay of cells in vitro. Nat Protoc;1:23152319.